Research progress of post-transplantation lymphoproliferative disease in children with adenotonsillar hypertrophy

doi:10.3760/cma.j.cn441417-20240724-05010

Abstract

Abstract:

Post-transplantation lymphoproliferative disease (PTLD) is a prevalent and diverse form of secondary malignancy observed in pediatric patients. The incidence of PTLD is higher in children than in adults, with a mortality rate reaching up to 20%. PTLD typically originates within the Waldeyer ring of the head and neck, presenting as adenotonsillar hypertrophy, tonsillitis, or cervical lymph node enlargement. Adenotonsillar hypertrophy in children is a common disease in otorhinolaryngology; when adenotonsillar hypertrophy occurs in post-transplant children, the possibility of PTLD should be alerted. Hence, this article comprehensively reviews the current research progress on the epidemiology, pathogenesis, clinical manifestations, diagnosis, and treatment of PTLD in children with adenotonsillar hypertrophy, aiming to enhance early identification, accurate diagnosis, and effective treatment of PTLD in children with adenotonsillar hypertrophy after their first transplantation, and improve the prognosis.

Key words:

Post-transplantation lymphoproliferative disease, Organ transplantation, Adenotonsillar hypertrophy, Epstein-Barr virus, Children, , Progress

摘要：

移植后淋巴组织增生性疾病（PTLD）为儿科常见疾病，具有异质性的继发性恶性肿瘤。儿童发病率高于成人，病死率为20%。PTLD常首发于头颈部Waldeyer环，表现为扁桃体腺样体肥大、扁桃体炎或颈部淋巴结肿大。儿童扁桃体腺样体肥大是耳鼻咽喉科常见疾病，移植后儿童出现扁桃体腺样体肥大，应警惕PTLD。本文综述PTLD在扁桃体腺样体肥大中的流行病学、发病机制、临床表现、诊断及治疗研究进展，旨在早期识别诊断和治疗PTLD，改善预后。

关键词:

移植后淋巴组织增生性疾病, 器官移植, 扁桃体腺样体肥大, EB病毒, 儿童, 进展

Zhang Han, Sun Ting, Wang Yanfei, Zhang Xiaolin, Che Juan.

Research progress of post-transplantation lymphoproliferative disease in children with adenotonsillar hypertrophy [J]. International Medicine and Health Guidance News, 2025, 31(5): 752-757.

张涵孙婷王延飞张肖林车娟.

移植后淋巴组织增生性疾病在儿童扁桃体腺样体肥大中的研究进展 [J]. 国际医药卫生导报, 2025, 31(5): 752-757.

References

[1] San-Juan R, Manuel O, Hirsch HH, et al. Current preventive strategies and management of Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplantation in Europe. Results of the ESGICH Questionnaire-based Cross-sectional Survey[J]. Clin Microbiol Infect, 2015, 21(6):604.e1-e9. DOI: 10.1016/j.cmi.2015.02.002.
[2] Engels EA, Pfeiffer RM, Fraumeni JF, et al. Spectrum of cancer risk among US solid organ transplant recipients[J]. JAMA, 2011, 306(17):1891-1901. DOI: 10.1001/jama. 2011.1592.
[3] 明英姿,彭博,成柯,等.实体器官移植后淋巴组织增生性疾病的研究进展[J].器官移植,2017,8(2):89-98.DOI:10.3969/j.issn.1674-7445.2017.02.002.
[4] Hellings P, Jorissen M, Ceuppens JL. The Waldeyer's ring[J]. Acta Otorhinolaryngol Belg, 2000,54(3):237-241.
[5] Hazkani I, Hajnas N, Victor M, et al. Tonsillectomy outcomes in children after solid-organ transplantation: a 15-year single-center experience[J]. Otolaryngol Head Neck Surg, 2023, 168(5):1209-1216. DOI: 10.1002/ohn.193.
[6] Sokal EM, Antunes H, Beguin C, et al. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus[J]. Transplantation, 1997, 64(10):1438-1442. DOI: 10.1097/00007890-199711270-00011.
[7] Zaffiri L, Long A, Neely ML, et al. Incidence and outcome of post-transplant lymphoproliferative disorders in lung transplant patients: analysis of ISHLT Registry[J]. J Heart Lung Transplant, 2020, 39(10):1089-1099. DOI: 10.1016/j.healun.2020.06.010.
[8] Zaffiri L, Chambers ET. Screening and management of PTLD[J]. Transplantation, 2023, 107(11):2316-2328. DOI: 10.1097/TP.0000000000004577.
[9] 艾亮,张盛,王强,等.EB病毒相关性移植后淋巴组织增生性疾病生物标志物的相关进展[J].器官移植,2021,12(6):767-772.DOI:10.3969/j.issn.1674-7445.2021.06.019.
[10] Khedmat H, Taheri S. Post-transplantation lymphoproliferative disorders localizing in the adenotonsillar region: report from the PTLD.Int survey[J]. Ann Transplant, 2011, 16(1):109-116.
[11] Murata T, Sugimoto A, Inagaki T, et al. Molecular basis of Epstein-Barr virus latency establishment and lytic reactivation[J]. Viruses, 2021, 13(12):2344. DOI: 10.3390/v13122344.
[12] Cheng J, Wistinghausen B. Clinicopathologic spectrum of pediatric posttransplant lymphoproliferative diseases following solid organ transplant[J]. Arch Pathol Lab Med, 2024, 148(9):1052-1062. DOI: 10.5858/arpa.2023- 0323-RA.
[13] Green M, Cacciarelli TV, Mazariegos GV, et al. Serial measurement of Epstein-Barr viral load in peripheral blood in pediatric liver transplant recipients during treatment for posttransplant lymphoproliferative disease[J]. Transplantation, 1998, 66(12):1641-1644. DOI: 10.1097/00007890-199812270-00012.
[14] Singavi AK, Harrington AM, Fenske TS. Post-transplant lymphoproliferative disorders[J]. Cancer Treat Res, 2015,165:305-327. DOI: 10.1007/978-3-319-13150-4_13.
[15] Jagadeesh D, Woda BA, Draper J, et al. Post transplant lymphoproliferative disorders: risk, classification, and therapeutic recommendations[J]. Curr Treat Options Oncol, 2012, 13(1):122-136. DOI: 10.1007/s11864-011- 0177-x.
[16] Allen UD, Preiksaitis JK; AST Infectious Diseases Community of Practice. Epstein-Barr virus and posttransplant lymphoproliferative disorder in solid organ transplantation[J]. Am J Transplant, 2013, 13 Suppl 4:107-120. DOI: 10.1111/ajt.12104.
[17] Quinlan SC, Pfeiffer RM, Morton LM, et al. Risk factors for early-onset and late-onset post-transplant lymphoproliferative disorder in kidney recipients in the United States[J]. Am J Hematol, 2011, 86(2):206-209. DOI: 10.1002/ajh.21911.
[18] Habermann TM. Posttransplant lymphoproliferative disorders[J]. Cancer Treat Res, 2008,142:273-292. DOI: 10.1007/978-0-387-73744-7_12.
[19] Allen UD, Preiksaitis JK; AST Infectious Diseases Community of Practice. Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice[J]. Clin Transplant, 2019, 33(9):e13652. DOI: 10.1111/ctr.13652.
[20] Song H, Guja KE, Iagaru A. 18F-FDG PET/CT for evaluation of post-transplant lymphoproliferative disorder (PTLD)[J]. Semin Nucl Med, 2021, 51(4):392-403. DOI: 10.1053/j.semnuclmed.2020.12.009.
[21] DeStefano CB, Desai SH, Shenoy AG, et al. Management of post-transplant lymphoproliferative disorders[J]. Br J Haematol, 2018, 182(3):330-343. DOI: 10.1111/bjh.15263.
[22] Zhang Y, Lv Y, Wang B, et al. Diagnosis and treatment of adult patients with PTLD at different sites after liver transplantation: a three-case report and literature review[J]. Transpl Immunol, 2023, 80:101881. DOI: 10.1016/j.trim.2023.101881.
[23] Campo E, Harris N L, Jaffe E S, et al. WHO classification of tumours of haematopoietic and lymphoid tissues[M]. Lyon: International agency for research on cancer, 2008.
[24] Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms[J]. Blood, 2016, 127(20):2375-2390. DOI: 10.1182/blood-2016-01-643569.
[25] Végso G, Hajdu M, Sebestyén A. Lymphoproliferative disorders after solid organ transplantation-classification, incidence, risk factors, early detection and treatment options[J]. Pathol Oncol Res, 2011, 17(3):443-454. DOI: 10.1007/s12253-010-9329-8.
[26] Crombie JL, LaCasce AS. Epstein Barr virus associated B-cell lymphomas and iatrogenic lymphoproliferative disorders[J]. Front Oncol, 2019, 9:109. DOI: 10.3389/fonc.2019.00109.
[27] Aguilera N, Gru AA. Reexamining post-transplant lymphoproliferative disorders: newly recognized and enigmatic types[J]. Semin Diagn Pathol, 2018, 35(4):236-246. DOI: 10.1053/j.semdp.2018.02.001.
[28] Shapiro NL, Tang CG, Bhattacharyya N. Association between Epstein-Barr virus seroconversion and immunohistochemical changes in tonsils of pediatric solid organ transplant recipients[J]. Laryngoscope, 2011, 121(8):1718-1725. DOI: 10.1002/lary.21871.
[29] Roy S, Vivero RJ, Smith LP. Adenotonsillar pathology in post-transplant patients[J]. Int J Pediatr Otorhinolaryngol, 2008, 72(6):865-868. DOI: 10.1016/j.ijporl.2008.02.016.
[30] Loevner LA, Karpati RL, Kumar P, et al. Posttransplantation lymphoproliferative disorder of the head and neck: imaging features in seven adults[J]. Radiology, 2000, 216(2):363-369. DOI: 10.1148/radiology.216.2.r00au24363.
[31] Heyes R, Northfelt DW, Lott DG. Posttransplant lymphoproliferative disorder: otolaryngological manifestations and management[J]. Otolaryngol Head Neck Surg, 2017, 157(5):750-759. DOI: 10.1177/0194599817707208.
[32] Guberina N, Gäckler A, Grueneisen J, et al. Assessment of suspected malignancy or infection in immunocompromised patients after solid organ transplantation by [18F]FDG PET/CT and [18F]FDG PET/MRI[J]. Nucl Med Mol Imaging, 2020, 54(4):183-191. DOI: 10.1007/s13139-020-00648-5.
[33] 麦东媚,沈乐,谭俊青.采用间接法建立BV-VCA-IgA和EBV-EA-IgA定量检测的参考区间[J].国际医药卫生导报,2023,29(10):1385-1391.DOI:10.3760/cma.j.issn.1007- 1245.2023.10.012.
[34] Mowry SE, Strocker AM, Chan J, et al. Immunohistochemical analysis and Epstein-Barr virus in the tonsils of transplant recipients and healthy controls[J]. Arch Otolaryngol Head Neck Surg, 2008, 134(9):936-939. DOI: 10.1001/archotol.134.9.936.
[35] AbuSalah MAH, Gan SH, Al-Hatamleh MAI, et al. Recent advances in diagnostic approaches for Epstein-Barr virus[J]. Pathogens, 2020, 9(3):226. DOI: 10.3390/pathogens9030226.
[36] Smatti MK, Al-Sadeq DW, Ali NH, et al. Epstein-Barr virus epidemiology, serology, and genetic variability of LMP-1 oncogene among healthy population: an update[J]. Front Oncol, 2018, 8:211. DOI: 10.3389/fonc.2018.00211.
[37] 刘静怡,孙丽莹,朱志军,等.儿童肝移植术后淋巴组织增殖性疾病临床分析[J].中华器官移植杂志,2019,40(7):404-409.DOI:10.3760/cma.j.issn.0254-1785.2019.07.006.
[38] Pan K, Franke AJ, Skelton WP 4th, et al. Reduction of immunosuppression for post-transplant lymphoproliferative disorder (PTLD): a single-center experience of allograft survival outcomes[J]. Leuk Lymphoma, 2021, 62(5):1123-1128. DOI: 10.1080/10428194.2020.1861266.
[39] Dierickx D, Tousseyn T, Gheysens O. How I treat posttransplant lymphoproliferative disorders[J]. Blood, 2015, 126(20):2274-2283. DOI: 10.1182/blood-2015-05- 615872.
[40] Green M, Michaels MG. Epstein-Barr virus infection and posttransplant lymphoproliferative disorder[J]. Am J Transplant, 2013, 13 Suppl 3:41-54; quiz 54. DOI: 10.1111/ajt.12004.
[41] De Diego JI, Prim MP, Hardisson D, et al. Post-transplant lymphoproliferative disease in tonsils of children with liver transplantation[J]. Int J Pediatr Otorhinolaryngol, 2001, 58(2):113-118. DOI: 10.1016/s0165-5876(01)00415-3.
[42] Quintanilla-Dieck L, Chinnadurai S, Wootten C, et al. Pediatric post-tonsillectomy hemorrhage in the setting of post-transplantation immunosuppression[J]. Int J Pediatr Otorhinolaryngol, 2017, 95:117-120. DOI: 10.1016/j.ijporl.2017.02.014.
[43] Chiang S, Vu MC, Nguyen M, et al. Adenotonsillar enlargement in pediatric organ transplant recipients: a cross-sectional analysis[J]. Otolaryngol Head Neck Surg, 2002, 127(1):109-114. DOI: 10.1067/mhn.2002.126476.
[44] Orlandi E, Iorio GC, Bartoncini S, et al. Role of radiotherapy in post-transplant lymphoproliferative disorders: three case reports and review of the literature[J]. Clin Lymphoma Myeloma Leuk, 2021, 21(4):e309-e316. DOI: 10.1016/j.clml.2020.11.006.
[45] Dierickx D, Habermann TM. Post-transplantation lymphoproliferative disorders in adults[J]. N Engl J Med, 2018, 378(6):549-562. DOI: 10.1056/NEJMra1702693.
[46] Chiou FK, Beath SV, Patel M, et al. Hypogammaglobulinemia and bacterial infections following pediatric post-transplant lymphoproliferative disorder in the rituximab era[J]. Pediatr Transplant, 2019, 23(6):e13519. DOI: 10.1111/petr.13519.
[47] Trappe R, Oertel S, Leblond V, et al. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial[J]. Lancet Oncol, 2012, 13(2):196-206. DOI: 10.1016/S1470-2045(11)70300-X.
[48] Parker A, Bowles K, Bradley JA, et al. Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients - BCSH and BTS Guidelines[J]. Br J Haematol, 2010, 149(5):693-705. DOI: 10.1111/j.1365-2141.2010.08160.x.
[49] Chiou FK, Beath SV, Wilkie GM, et al. Cytotoxic T-lymphocyte therapy for post-transplant lymphoproliferative disorder after solid organ transplantation in children[J]. Pediatr Transplant, 2018, 22(2). DOI: 10.1111/petr.13133.
[50] Taylor AL, Marcus R, Bradley JA. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation[J]. Crit Rev Oncol Hematol, 2005, 56(1):155-167. DOI: 10.1016/j.critrevonc.2005.03.015.
[51] Walti LN, Mugglin C, Sidler D, et al. Association of antiviral prophylaxis and rituximab use with posttransplant lymphoproliferative disorders (PTLDs): a nationwide cohort study[J]. Am J Transplant, 2021, 21(7):2532-2542. DOI: 10.1111/ajt.16423.
[52] Liu L, Liu Q, Feng S. Management of Epstein-Barr virus-related post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation[J]. Ther Adv Hematol, 2020, 11:2040620720910964. DOI: 10.1177/2040620720910964.
[53] Rossignol J, Terriou L, Robu D, et al. Radioimmunotherapy ((90) Y-ibritumomab tiuxetan) for posttransplant lymphoproliferative disorders after prior exposure to rituximab[J]. Am J Transplant, 2015, 15(7):1976-1981. DOI: 10.1111/ajt.13244.